A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Launched by ELI LILLY AND COMPANY · Apr 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called Eloralintide (LY3841136) to see how well it is tolerated and what side effects it might cause in Chinese participants who are overweight or obese. The goal is to understand how the body processes this medication and how long it stays in the bloodstream. The study will last about 10 weeks, not including an initial screening period where participants will be evaluated for eligibility.

To join the study, participants need to be Chinese, meaning all four of their grandparents must be of Chinese descent. They should have a stable body weight for at least three months and should not have made significant changes to their diet during that time. Eligible participants should have a body mass index (BMI) between 27 and 40, which indicates that they are overweight or obese. Throughout the trial, participants will receive the medication through an injection under the skin and will have regular check-ups to monitor their health and any side effects. It’s important to note that certain health conditions and other factors may exclude individuals from participating, such as pregnancy, significant heart or kidney issues, or a history of substance abuse.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
• • Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
• • Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
• • Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator
• • Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)
• Exclusion Criteria:
• • Are pregnant, or intend to become pregnant or to breastfeed during the study
• • Have known allergies to related compounds of eloralintide
• * Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator:
• • Supine BP \> 160/90 millimeter mercury (mmHg)
• • Supine pulse rate \< 50 or \> 100 beats per minute (bpm)
• • Orthostatic hypotension
• • Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
• • Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
• • Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
• • Have a history of chronic medical conditions involving the heart, liver, or kidneys
• • Have a medical history or current evidence of clinically significant cardiac condition